An observational study in COVID 19, sponsored by National Research Center for Preventive Medicine. Active, not recruiting at 2 sites in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-30.
Sponsored by National Research Center for Preventive Medicine · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 144 studies in COVID-19 with a site in Russian Federation — 4 open to participants now, 9 under way, 1 of them phase 3. COVID-19 · Russian Federation.
Among the 144 studies in COVID-19 with a site in Russian Federation, this one is the 10th largest by enrollment of the 39 observational ones that give a count, is one of 86 that started in 2020, is one of 39 observational ones, and was the 37th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →4 of the 144 studies in COVID-19 with a site in Russian Federation are open now. Recruiting first, the newest first:
Masaryk University · Sites in Russian Federation, United States, Canada and 11 more countries
Ages 18+
Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department · Sites in Russian Federation
Ages 18+ · Healthy volunteers
I.M. Sechenov First Moscow State Medical University · Sites in Russian Federation
Ages 18–80
Valenta Pharm JSC · Sites in Russian Federation
Ages 18–45 · Healthy volunteers
A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
144 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 41 · Phase 3 51 · Phase 4 6
First in 2018; this study’s year is marked. 86 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,130 is above the median of 268 across 3,209 observational studies indexed under COVID-19.
Median enrollment 198 across the 105 interventional studies, 220 across the 39 observational. Of the 107 that completed or were terminated, 27 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 144 have an industry lead sponsor. The 10 most frequent:
National Research Center for Preventive Medicine is the lead sponsor of 18 studies on the registry; none are open to participants now.
National Research Center for Preventive Medicine has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
1 of the studies in COVID-19 with a site in Russian Federation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04522076National Research Center for Preventive MedicineProspective Hospital Registry of Patients With Suspected or Confirmed Coronavirus Infection (COVID-19) and Community-acquired Pneumonia | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 144 studies in COVID-19 with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Coronavirus-2019 disease (COVID-19) and community-acquired pneumonia are significant problems of modern medicine. Pneumonia is the most common severe complication of COVID-19. But at the same time, COVID-19 is not the only cause of community-acquired pneumonia. Moreover, pneumonia is only one of the numerous possible severe complications of COVID-19. Medical centers specialized for the hospital treatment of patients with severe COVID-19 and community-acquired pneumonia were organized in different regions of Russia during coronavirus pandemic-2020. The indications for hospitalization to one of these centers based in the National Medical and Surgical Center (NMSC) are: confirmed or suspected severe COVID-19 or community-acquired pneumonia.
A prospective medical registry of such patients hospitalized to NMSC, is intended to analyze and compare their clinical and instrumental data, co-morbidity, treatment, short-term and long-term outcomes in real clinical practice.
Stage 1. Hospital treatment in NMSC
Duration of this stage: from the date of admission to the hospital up to the date of discharge from the hospital / or up to the date of death during the reference hospitalization. The date of admission to the hospital will be the date of enrollment to the study.
Evaluation of electronic health record data using the Medical Information System (MIS). Assessment of the outcomes of the hospital phase (discharge from the hospital, death) and significant events (acute respiratory and pulmonary failure, requiring mechanical ventilation; cardiovascular events - myocardial infarction, cerebral stroke, acute heart failure, paroxysmal heart rhythm disturbances, bleedings, thrombosis of large vessels and thromboembolic complications). A survey of patients to clarify data on risk factors, somatic diseases, and drug therapy before hospitalization.
COVID-19 was diagnosed when severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was confirmed by Polymerase chain reaction (PCR). Pneumonia was confirmed according to computerized tomography (CT) data.
Stage 2. Prospective outpatient follow-up for 24 months
Duration of this stage: 24 months after discharge from the hospital This work will be delivered by investigators from the National Medical Research Center for Therapy and Preventive Medicine.
Evaluation of long-term outcomes and events among residents of Moscow and the Moscow Region according to a patient survey (contact by phone for 30-60 days, 6 months, 12 and 24 months after discharge from the hospital) and medical records.
From April 6, 2020 until the end of the work period of departments of NMSC, that are specialized for the treatment of patients with COVID-19 and community-acquired pneumonia all patients with inclusion criteria and who don't have exclusion criteria will be included in the study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
patients with positive COVID 19 by PCR and pneumonia by CT
patients with positive COVID 19 by PCR and absent of pneumonia by CT
patients with negative COVID 19 by PCR and with pneumonia by CT
Patients with suspected COVID-19 and/or pneumonia at the pre-hospital stage that were not confirmed in hospital
Overall survival
Time frame: from admission to discharge or death during reference hospitalization, assessed up to 90 days
Time to all-cause mortality or Artificial Pulmonary Ventilation (APV)
Time frame: from admission to discharge or death during reference hospitalization, assessed up to 90 days
Time to all-cause mortality, nonfatal myocardial infarction, nonfatal cerebral stroke, and coronary or carotid revascularization
Time frame: from discharge up to two years after reference hospitalization
Proportion of patients with severe pneumonia
Damage area \>50% according to the computer tomography data at any time point during hospitalization
Time frame: from admission to discharge or death during reference hospitalization, assessed up to 90 days
Proportion of patients with low oxygen saturation value
SpO2 \<90% - at any point during hospitalization
Time frame: from admission to discharge or death during reference hospitalization, assessed up to 90 days
Proportion of patients with Hb <90 g/l (9.0 g/dl) at any point during hospitalization
Time frame: from admission to discharge or death during reference hospitalization, assessed up to 90 days
Proportion of patients hospitalized or transferred to Intensive Care Unit (ICU)
Time frame: from admission to discharge or death during reference hospitalization, assessed up to 90 days
Overall survival
Time frame: from discharge up to two years after reference hospitalization
Time to nonfatal myocardial infarction, nonfatal cerebral stroke, and coronary or carotid revascularization
Time frame: from discharge up to two years after reference hospitalization
Time to pneumonia/recurrent pneumonia
In patients with pneumonia during reference hospitalization time to recurrent pneumonia. In patients without pneumonia during reference hospitalization - time to first pneumonia
Time frame: from discharge up to two years after reference hospitalization
Time to primary or recurrent coronavirus infection disease (COVID-19)
In patients without COVID-19 - time to primary diagnosis and in patients with COVID-19 - time to recurrent event
Time frame: from discharge up to two years after reference hospitalization
proportion of patients with nonfatal myocardial infarction
Time frame: from admission to discharge or death during reference hospitalization, assessed up to 90 days
proportion of patients with nonfatal cerebral stroke
Time frame: from admission to discharge or death during reference hospitalization, assessed up to 90 days
proportion of patients with bleedings
Time frame: from admission to discharge or death during reference hospitalization, assessed up to 90 days
thromboembolic events
proportion of patients with thromboembolic events
Time frame: from admission to discharge or death during reference hospitalization, assessed up to 90 days
Duration of Artificial Pulmonary Ventilation
the sum of the days when the patients required artificial pulmonary ventilation
Time frame: from admission to discharge or death during reference hospitalization, assessed up to 90 days
Minimal value of oxygen blood saturation (SpO2) during the hospital stage.
Time frame: from admission to discharge or death during reference hospitalization, assessed up to 90 days
Minimal value of hemoglobin (Hb) during the hospital stage
Time frame: from admission to discharge or death during reference hospitalization, assessed up to 90 days
Rehospitalization due to pneumonia, COVID-19, flu and other acute respiratory infections (ARV)
proportion of patients with rehospitalization due to pneumonia, COVID-19, flu and other acute respiratory infections (ARV)
Time frame: from discharge up to two years after reference hospitalization
Hospitalization due to cardiovascular disease (CVD)
proportion of patients with hospitalization due to cardiovascular disease
Time frame: from discharge up to two years after reference hospitalization
time to Flu and other ARV (except COVID-19)
Time frame: from discharge up to two years after reference hospitalization
Started Apr 2020 (actual). Primary completion is estimated for Dec 2026, 80 months after the start.
Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 80 months is above that.
Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Research Center for Preventive Medicine